Valneva/$VALN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Valneva

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Ticker

$VALN
Primary listing

Industry

Biotechnology

Employees

713

ISIN

US92025Y1038

Valneva Metrics

BasicAdvanced
$463M
-
-$0.62
1.10
-

Bulls say / Bears say

Valneva raised its 2024 product sales guidance to €170-190 million, anticipating growth from its travel vaccines and the launch of IXIARO® (reuters.com)
The company significantly reduced its net loss from €101.4 million in 2023 to €12.2 million in 2024, aided by the sale of a Priority Review Voucher (tipranks.com)
Valneva's Lyme disease vaccine candidate, VLA15, is progressing in Phase 3 trials, with first results expected by the end of 2025, potentially leading to significant future revenues (tipranks.com)
Valneva's total revenues dropped to €153.7 million in 2023 from €361.3 million in 2022, missing analyst estimates of €171.7 million (reuters.com)
The company reported an operating loss of €82.1 million in 2023, though reduced from €113.4 million in 2022, indicating ongoing profitability challenges (valneva.com)
Valneva's debt-to-equity ratio stands at 103.4%, reflecting a high level of debt relative to equity, which may pose financial risks (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VALN

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs